3 Stocks Pulling The Health Services Industry Downward

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 19 points (-0.1%) at 15,282 as of Wednesday, July 10, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,222 issues advancing vs. 1,685 declining with 126 unchanged.

The Health Services industry currently sits down 0.1% versus the S&P 500, which is down 0.1%. Top gainers within the industry include Intuitive Surgical ( ISRG), up 1.6%, Agilent Technologies ( A), up 1.7%, Quest Diagnostics ( DGX), up 1.4%, CareFusion ( CFN), up 1.4% and Laboratory Corporation of America Holdings ( LH), up 1.3%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Bio-Reference Labs ( BRLI) is one of the companies pushing the Health Services industry lower today. As of noon trading, Bio-Reference Labs is down $2.21 (-7.7%) to $26.46 on heavy volume. Thus far, 727,867 shares of Bio-Reference Labs exchanged hands as compared to its average daily volume of 339,300 shares. The stock has ranged in price between $26.28-$28.24 after having opened the day at $28.22 as compared to the previous trading day's close of $28.67.

Bio-Reference Laboratories, Inc. provides clinical laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases primarily in the greater New York metropolitan area. Bio-Reference Labs has a market cap of $821.0 million and is part of the health care sector. Shares are up 3.7% year to date as of the close of trading on Tuesday. Currently there are 3 analysts that rate Bio-Reference Labs a buy, 1 analyst rates it a sell, and none rate it a hold.

TheStreet Ratings rates Bio-Reference Labs as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Bio-Reference Labs Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Cramer -- Shun Sears, Delta; Nike Beats Under Armour (Unless Curry Finds His Shot)

Cramer: Strong Dollar Means Own Stocks Like UnitedHealth, Humana

Perilous Reversal Stock: Bio-Reference Laboratories (BRLI)

Bio-Reference Labs (BRLI) Stock Gains on Acquisition Despite Earnings Miss

Change at the Top for Two Banks; High Hopes for Cisco